Kate Haviland, CHIEF EXECUTIVE OFFICER at Blueprint Medicines Corp (BPMC), sold 4,099 shares at $96.74 ($396K) on 2024-11-29, disclosed to the SEC on 2024-12-03.
Scheduled sale ($396k) by CHIEF EXECUTIVE OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $95.40 | 400 | $38K | 9.6% |
| 2 | $96.74 | 1,746 | $169K | 42.6% |
| 3 | $96.74 | 1,746 | $169K | 42.6% |
| 4 | $97.76 | 207 | $20K | 5.1% |
| Total | $96.66 avg | 4,099 | $396K | 100% |
| Filing → |
| BPMC | SELL | 2025-01-23 | $319K | — | Filing → |
| BPMC | SELL | 2024-03-11 | $2.3M | — | Filing → |
| BPMC | SELL | 2023-03-08 | $597K | — | Filing → |